VLA | Jotup

EPS Learning Programs Selected by Virginia Board of Education as Recommended Literacy Solutions

Retrieved on:

Monday, April 15, 2024

Family, VLA, Learning, Vocabulary, Risk, SPIRE, Education, Comprehension, School, Literacy, SOL, Curriculum, Legislation, EPS, Recipe, Student, Tutoring

BETHESDA, Md., April 15, 2024 /PRNewswire-PRWeb/ -- EPS Learning, the leading provider of PreK-12 literacy solutions, announced that four of its programs have been recommended by the Virginia Board of Education for evidence-based literacy instruction that's aligned to science-based reading research. The recognition supports Virginia schools in a multi-year effort to improve early learning outcomes for students who are below proficiency levels in reading.

Key Points:

BETHESDA, Md., April 15, 2024 /PRNewswire-PRWeb/ -- EPS Learning , the leading provider of PreK-12 literacy solutions, announced that four of its programs have been recommended by the Virginia Board of Education for evidence-based literacy instruction that's aligned to science-based reading research.
"We champion Virginia's significant efforts to ensure that all students in the state can access literacy as the springboard to lifelong learning and opportunity."
To remedy reading proficiency beginning in the 2024–2025 school year, the Virginia Literacy Act (VLA) will mandate core literacy and research-grounded instruction for K–5 students.
EPS Learning programs meet the required parameters to be recommended as top literacy intervention solutions, including alignment with evidence-based literacy instruction, comprehensive and intensive intervention, support that is accessible and can be easily implemented into any curriculum, inclusivity and representation.

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Retrieved on:

Tuesday, March 26, 2024

Notifiable disease, Saint-Herblain, Zika virus, JE, COVID-19, VLA2001, Ageing, Public, Chikungunya, Woman, Mosquito-borne disease, VLA, Safety, Euronext Paris, Access, CpG, Food, Vaccine

Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the

Key Points:

Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the
the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV).
The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to 49 years in the United States.
Phase 1 results from Valneva’s first-generation Zika vaccine candidate were reported in 2018 showing a favorable safety profile and immunogenicity in all tested doses and schedules2.
This preference stems from the understanding that the primary recipients of a Zika vaccine are anticipated to be women of childbearing age, potentially including those who are pregnant.

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

Retrieved on:

Monday, March 25, 2024

Saint-Herblain, URD, VLA, Euronext Paris, File, AMF, Cryptocurrency

Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).

Key Points:

Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).
Valneva’s 2023 Universal Registration Document – available in its entirety in French – includes the Company’s 2023 Annual Financial Report, the Company's Annual Management Report, the Board of Directors’ Corporate Governance Report and the Company’s Sustainability Report.
These documents are available on Valneva’s website ( https://valneva.com/investors/financial-reports/ ) and will also be available on the AMF ( www.amf-france.org/ ) and SEC ( www.sec.gov/ ) websites, respectively.
Hard copies of these documents may be obtained from the Company, free of charge, upon request at the following address: 6 rue Alain Bombard, 44800 Saint-Herblain, France.

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Retrieved on:

Thursday, March 21, 2024

The Company will have a display in the exhibit area of the congress at booth #433.

Key Points:

The Company will have a display in the exhibit area of the congress at booth #433.
There will be two sessions, from 11:40 to 12:20 EST and again from 12:30 to 1:10pm EST.
Advisory Committee on Immunization Practices (ACIP)1 and these recommendations were adopted by the Centers for Disease Control and Prevention (CDC)2.
Additionally, Valneva CEO Thomas Lingelbach will present the Best Production / Process Development award at the event.

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

Retrieved on:

Monday, March 18, 2024

Euronext Paris, OrbiMed, Saint-Herblain, VLA, Airline

Reimbursements of the first $100 million tranche will now start in January 2026 instead of July 2024.

Key Points:

Reimbursements of the first $100 million tranche will now start in January 2026 instead of July 2024.
Maturity of this first tranche will remain in the first quarter of 2027.
Peter Bühler, Chief Financial Officer of Valneva, said, “We greatly appreciate the continued support from Deerfield and OrbiMed.
Valneva announced amendments to the terms in January 20212 and upsizing in April 20223 and August 20234.

Aircraft Engine Test Cells Market worth $4.1 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Thursday, March 14, 2024

The market for aircraft engine test cell solutions has been divided into four segments based on engine tests: piston engine, APU, turbofan, turbojet, and turboshaft (Auxiliary Power Unit).

Key Points:

The market for aircraft engine test cell solutions has been divided into four segments based on engine tests: piston engine, APU, turbofan, turbojet, and turboshaft (Auxiliary Power Unit).
Due to its superior altitude capability over other engine types, turbofans are expected to dominate the aircraft engine test cells market throughout the forecast period.
Based on solution type, the test cells segment is projected to lead the aircraft engine test cells industry during the forecast period.
The market for aircraft engine test cell solutions has been divided into test cell, component test bench, software, ancillary system, and data acquisition & control system.

Aircraft Engine Test Cells Market worth $4.1 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Thursday, March 14, 2024

The market for aircraft engine test cell solutions has been divided into four segments based on engine tests: piston engine, APU, turbofan, turbojet, and turboshaft (Auxiliary Power Unit).

Key Points:

The market for aircraft engine test cell solutions has been divided into four segments based on engine tests: piston engine, APU, turbofan, turbojet, and turboshaft (Auxiliary Power Unit).
Due to its superior altitude capability over other engine types, turbofans are expected to dominate the aircraft engine test cells market throughout the forecast period.
Based on solution type, the test cells segment is projected to lead the aircraft engine test cells industry during the forecast period.
The market for aircraft engine test cell solutions has been divided into test cell, component test bench, software, ancillary system, and data acquisition & control system.

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Retrieved on:

Monday, March 4, 2024

Pfizer, ACIP, Indoor Living, Conference, VLA, CHMP, Saint-Herblain, Chikungunya, Euronext Paris

Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe.

Key Points:

Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe.
CEO Thomas Lingelbach will present Valneva at the TD Cowen 44th Annual Health Care Conference, taking place March 4 - 6, 2024, in Boston, MA.
Mr. Lingelbach and CFO Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen Life Sciences Conference, held April 16 - 17, 2024, in Amsterdam, The Netherlands.
VLA15, the Company’s Lyme disease vaccine candidate, is currently in Phase 3 clinical development and partnered with Pfizer for this study and global commercialization.

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

Retrieved on:

Thursday, February 29, 2024

ACIP, Person, MD, FDA, Food, Risk, VLA, Vaccination, MMWR, Food and Drug Administration, Family, Saint-Herblain, Disease, CDC, Chikungunya, Ageing, Euronext Paris, Vaccine

ACIP recommends IXCHIQ® for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak.

Key Points:

ACIP recommends IXCHIQ® for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak.
ACIP also recommended chikungunya vaccination for laboratory workers with potential for exposure to CHIKV.
IXCHIQ offers advantages to travelers on vacation and visiting family and to people engaged in business ventures, missions, or laboratory duties.
We embrace the ACIP endorsement, marking IXCHIQ® as the only approved and recommended vaccine for the target population.

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

Retrieved on:

Thursday, February 15, 2024

Total, Bavarian Nordic, Investment, Cash, Growth, Sale, Government, VLA, COVID-19, COVID, Third party, PRV, Chikungunya, Bank statement, Euronext Paris, Travel, OrbiMed

The Company will publish its 2023 audited consolidated financial statements on March 20, 2024.

Key Points:

The Company will publish its 2023 audited consolidated financial statements on March 20, 2024.
Peter Bühler, Valneva’s Chief Financial Officer, commented, “In 2023, Valneva successfully executed on key strategic objectives despite a difficult economic environment.
Total revenues in 2022 included €280.0 million of revenue recognition mainly related to the COVID-19 supply agreements in the prior year.
Other income is anticipated between €95 million and €105 million, including the PRV sold in early 2024 for €95 million.